DFINE is committed to building scientific evidence to support the use of our products. Our latest, the STAR™ Tumor Ablation System, received FDA 510(k) clearance in 2010, and is now involved in the The Evaluation of Combined RF Ablation and Cement Delivery in Painful Tumors of the Spine Trial (AbCT) in the European Union.
The AbCT Trial is the first prospective study to focus on the substantial palliative benefits of targeted tumor ablation in the interventional oncology arena involving the spine. This approach combines DFINE’s core technologies – specifically radiofrequency energy, navigational instrumentation, and ultra-high viscosity bone cement with extended working time – to create an extension of our RF platform. It represents a major milestone for cancer patients and for DFINE.
Moving forward the company continues to invest in clinical studies to further improve the quality of life for patients suffering from metastatic and vertebral pathologies.
Physicians' insights on RF Ablation
STAR Tumor Ablation Procedure